Advanced Biomed Inc. Announces 1 for 20 Share Consolidation

Core Viewpoint - Advanced Biomed Inc. announced a reverse stock split at a ratio of 1 for 20 shares, effective February 20, 2026, to comply with Nasdaq Listing Rule 5550(a)(2) [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split was approved by a majority of the voting power on January 12, 2026, with the board finalizing the ratio on January 30, 2026 [2]. - The objective of the reverse split is to enable the company to meet the minimum bid price requirement of $1.00 per share on Nasdaq [3]. - Following the reverse split, the total issued and outstanding common shares will decrease from 27,290,710 to approximately 1,364,536 shares [6]. Group 2: Shareholder Impact - Each 20 shares will convert into one share, maintaining the par value of US$0.001, and will not alter stockholders' percentage ownership, except for minor changes due to fractional shares [4]. - No fractional shares will be issued; stockholders will receive one full share instead of any fractional share resulting from the split [5]. Group 3: Company Overview - Advanced Biomed Inc. is a biotechnology company focused on innovative biomedical products for precision medicine and advanced diagnostics [1][7]. - The company operates through a subsidiary in Taiwan and has developed a proprietary microfluidic platform for advanced circulating tumor cell detection and analysis [8].